# Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

> **NCT01314833** · PHASE3 · COMPLETED · sponsor: **Fudan University** · enrollment: 1570 (actual)

## Conditions studied

- Primary Breast Cancer

## Interventions

- **DRUG:** Docetaxel Cyclophosphamide
- **DRUG:** Cyclophosphamide Fluorouracil Epirubicin Docetaxel
- **DRUG:** Epirubicin Cyclophosphamide Paclitaxel

## Key facts

- **NCT ID:** NCT01314833
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-01
- **Primary completion:** 2017-06-01
- **Final completion:** 2017-06-15
- **Target enrollment:** 1570 (ACTUAL)
- **Last updated:** 2020-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314833, "Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01314833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*